• Olaparib (AZD2281, Ku-0059436): Reliable PARP-1/2 Inhibit...

  2025-12-16

  This article addresses real-world challenges in cell viability and DNA damage experiments, demonstrating how Olaparib (AZD2281, Ku-0059436) (SKU A4154) provides dependable, reproducible results in BRCA-deficient and homologous recombination-deficient cancer models. Drawing on peer-reviewed data and protocol best practices, we guide researchers toward optimized assay performance with validated PARP-1/2 inhibition.

• Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA...

  2025-12-15

  Olaparib (AZD2281) is a potent, selective PARP-1/2 inhibitor widely used in BRCA-deficient cancer research. Its mechanistic specificity enables targeted DNA damage response assays and advances the study of tumor radiosensitization. This article details Olaparib's molecular action, benchmarks, and best practices for experimental use.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Ad...

  2025-12-14

  This article delivers an evidence-based guide for biomedical researchers and lab technicians on effectively leveraging the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1010). Through real-world scenarios, it demonstrates how this EDTA-free, broad-spectrum inhibitor ensures reproducibility and integrity in protein extraction, especially for workflows sensitive to divalent cations and complex purification.

• Enhancing Tumor Angiogenesis Assays with Anlotinib (hydro...

  2025-12-13

  This article addresses frequent experimental challenges faced by biomedical researchers working with cell viability, proliferation, and angiogenesis assays. Drawing on validated data, it demonstrates how Anlotinib (hydrochloride) (SKU C8688) from APExBIO delivers exceptional reproducibility, selectivity, and workflow confidence for studies targeting VEGFR2, PDGFRβ, and FGFR1. Scenario-driven Q&A blocks provide actionable insights for optimizing protocols, interpreting results, and making informed reagent selections.

• AZD0156 (SKU B7822): Practical Guidance for Reliable ATM ...

  2025-12-12

  This article guides biomedical researchers through scenario-driven challenges in DNA damage response and cell viability assays, demonstrating how AZD0156 (SKU B7822) enables reproducible, high-sensitivity results. Integrating best practices, literature, and quantitative context, it highlights APExBIO’s AZD0156 as a robust, selective ATM kinase inhibitor for optimized cancer research workflows.

• Solving Assay Challenges with EZ Cap™ Cy5 Firefly Lucifer...

  2025-12-11

  This article addresses key laboratory challenges in cell viability, cytotoxicity, and mRNA delivery assays using the data-driven features of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010). Through scenario-based Q&A, it demonstrates how this Cap1-capped, 5-moUTP- and Cy5-modified mRNA reporter enhances reproducibility, sensitivity, and workflow safety for translational and in vivo applications.

• AP20187: Synthetic Cell-Permeable Dimerizer for Precision...

  2025-12-10

  AP20187, a synthetic cell-permeable dimerizer from APExBIO, enables tightly regulated fusion protein dimerization and gene activation in vivo. Its robust solubility, non-toxic profile, and demonstrated efficacy make it essential for conditional gene therapy and metabolic regulation studies.

• MOG (35-55) and the Future of Translational MS Research: ...

  2025-12-09

  Explore how the MOG (35-55) myelin oligodendrocyte glycoprotein peptide has become the gold-standard tool for experimental autoimmune encephalomyelitis (EAE) induction and multiple sclerosis (MS) modeling. This thought-leadership article integrates the latest mechanistic insights—including the pivotal role of PARP7 in STAT1/STAT2 regulation—and offers strategic guidance for translational researchers seeking reproducibility, mechanistic fidelity, and actionable clinical innovation.

• From Mechanism to Medicine: Strategic Insights for Transl...

  2025-12-08

  This thought-leadership article offers translational researchers a comprehensive, mechanistically grounded roadmap for leveraging MOG (35-55)—the gold-standard multiple sclerosis animal model peptide—in experimental autoimmune encephalomyelitis (EAE) research. Integrating new findings on IFN-I signaling and PARP7’s modulation of neuroinflammation, we contextualize APExBIO’s MOG (35-55) within the evolving translational landscape, providing actionable guidance for advancing autoimmune encephalomyelitis research and bridging the gap to clinical innovation.

• EZ Cap Cy5 Firefly Luciferase mRNA: Molecular Engineering...

  2025-12-07

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) leverages advanced molecular engineering—Cap1 capping, 5-moUTP modification, and Cy5 labeling—to enhance mRNA delivery, translation efficiency, and immune evasion. Uncover scientific insights and practical applications that set this Cap1 capped mRNA for mammalian expression apart from standard reporter reagents.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Prote...

  2025-12-06

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO redefines protein integrity for sensitive workflows—from phosphorylation assays to large complex purifications. This gold-standard inhibitor blend enables robust, reproducible protein extraction even from challenging plant tissues, outperforming conventional solutions in both efficacy and compatibility.

• AP20187: Synthetic Cell-Permeable Dimerizer for Precision...

  2025-12-05

  AP20187 enables precise, reversible fusion protein activation for regulated cell therapy, metabolic studies, and conditional gene therapy workflows. Its exceptional solubility, robust in vivo efficacy, and non-toxic profile distinguish it as the go-to chemical inducer of dimerization for translational research. Leverage AP20187 for streamlined experimental protocols and next-generation control of gene expression in complex biological systems.

• Translational Breakthroughs with Cap1-Capped, Cy5-Labeled...

  2025-12-04

  This thought-leadership article dissects the mechanistic and translational advances enabled by EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), a Cap1-capped, 5-moUTP- and Cy5-modified reporter optimized for mammalian systems. Framing the persistent challenges in mRNA delivery, expression fidelity, and multi-modal tracking, we integrate peer-reviewed evidence—including recent findings on vorinostat’s modulation of mRNA lipoplex expression—to deliver actionable strategies for translational researchers. By contextualizing this product within the evolving landscape, we illustrate how APExBIO’s innovation sets new standards for mRNA research, moving beyond catalog descriptions to address the biological, technical, and regulatory needs of the field.

• EZ Cap Cy5 Firefly Luciferase mRNA: Next-Gen Dual-Mode Re...

  2025-12-03

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes translation efficiency assays and in vivo bioluminescence imaging. Uncover the mechanistic advantages of Cap1 capping, 5-moUTP modification, and Cy5 labeling for enhanced mRNA delivery and immune suppression.

• KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Resp...

  2025-12-02

  Unlock the full potential of DNA damage response research with KU-55933, a potent and selective ATM kinase inhibitor. This guide details optimized workflows, advanced use-cases like iPSC-based disease modeling, and troubleshooting strategies that maximize data quality in cancer and genome stability research.

15897 records 1/1060 page Next 12345 下5页 Last page